Top Markets
Coin of the day
IDL Diagnostics AB (publ) IDL Diagnostics AB (publ)

IDL Diagnostics AB (publ)

IDLDX
Rank in Stocks #32453
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops... Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Share Price
$0.04367217
Last synced: 2026-08-17
Market Cap
$10.06M
Change (1 day)
3.99%
Change (1 year)
-26.77%
Country
SE
Trade IDL Diagnostics AB (publ) (IDLDX)

Category

Revenue for IDL Diagnostics AB (publ) (IDLDX)
Revenue in Aug 2026 TTM: 0
According to IDL Diagnostics AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for IDL Diagnostics AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$46.34B -
US
$25.11B -
US
- -
CN
$2.71B -
US
$4.55B -
US